Raltegravir - Open Access .click

Results 31 to 40 of about 12,405 (251)

Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing

CPT: Pharmacometrics & Systems Pharmacology, 2019
Raltegravir readily crosses the placenta to the fetus with maternal use during pregnancy. After birth, neonatal raltegravir elimination is highly variable and often extremely prolonged, with some neonates demonstrating rising profiles after birth despite
Jos Lommerse +10 more
doaj +1 more source

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. [PDF]

PLoS ONE, 2012
Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a
Robert A Smith +10 more
doaj +1 more source

Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110).

Journal of Acquired Immune Deficiency Syndromes, 2020
BACKGROUND Adequate pharmacokinetic and safety data in neonates are lacking for most antiretroviral agents. Raltegravir is a selective HIV-1 integrase strand transfer inhibitor (INSTI) available in a granule formulation suitable for use in neonates and ...
D. Clarke +14 more
semanticscholar +1 more source

Pharmacokinetics of the raltegravir/maraviroc/etravirine combination [PDF]

Journal of Antimicrobial Chemotherapy, 2011
n ...
CALCAGNO, Andrea +7 more
openaire +4 more sources

Differential effects of integrase strand transfer inhibitors, elvitegravir and raltegravir, on oligodendrocyte maturation: A role for the integrated stress response

Glia, 2020
Regardless of adherence to combined antiretroviral therapy, white matter and myelin pathologies persist in patients with HIV‐associated neurocognitive disorders, a spectrum of cognitive, motor, and behavioral impairments.
Lindsay M. Roth +7 more
semanticscholar +1 more source

Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.

Nephrology, Dialysis and Transplantation, 2020
BACKGROUND Increasing first-line treatment failures in low- and middle-income countries (LMICs) have led to increased use of integrase strand transfer inhibitors (INSTIs) such as dolutegravir.
E. Ndashimye +13 more
semanticscholar +1 more source

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

Frontiers in Cellular and Infection Microbiology, 2023
IntroductionSecond-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings.
José Ramón Santos +64 more
doaj +1 more source

Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings

Microbiology Spectrum, 2022
To ensure the long-term efficacy of dolutegravir (DTG), we evaluated the genotypic profile in viral reservoirs among patients on third-line (3L) antiretroviral therapy (ART) in Cameroon, according to prior exposure to raltegravir (RAL).
Joseph Fokam +31 more
doaj +1 more source

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens

Antimicrobial Resistance and Infection Control, 2020
Background Sub-Saharan African countries are transitioning to dolutegravir-based regimens, even for patients with extensive previous drug exposure, including first-generation integrase strand-transfer inhibitors (INSTI) such as raltegravir. Such exposure
J. Fokam +23 more
semanticscholar +1 more source

Effects of Omeprazole on Plasma Levels of Raltegravir [PDF]

Clinical Infectious Diseases, 2009
Raltegravir, a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has pH-dependent solubility. Raltegravir plasma concentration increases with omeprazole coadministration in healthy subjects; this is likely secondary to an increase in bioavailability attributable to increased gastric pH.
Julie A. Stone +15 more
openaire +3 more sources

antiretroviral therapy
viral load
human immunodeficiency virus hiv

virology
humans
integrase inhibitor

raltegravir potassium
3. good health
pharmacology